- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07165730
- Original Trial
Virtual Health Coaching With Artificial Intelligence for Glycemic Control in Type 2 Diabetes (DIACOACH-AI)
Effectiveness of Virtual Health Coaching Based on Artificial Intelligence to Improve Glycemic Control in Patients With Type 2 Diabetes Mellitus
Study Overview
Status
Conditions
Detailed Description
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by elevated blood glucose levels due to impaired insulin production or insulin resistance. Globally, the prevalence of T2DM continues to rise, and in Indonesia the number of cases has surpassed 10 million, placing the country among the top seven worldwide for diabetes prevalence. Poor glycemic control leads to serious complications such as kidney disease, cardiovascular disorders, and neuropathy, which reduce patients' quality of life and increase health care costs. One of the main challenges in diabetes management is the low level of patient adherence to recommended lifestyle changes, including diet, physical activity, and regular monitoring. Patients often struggle to maintain long-term self-management because of limited access to continuous education, motivation, and personalized support in primary health care settings.
Digital health innovations, including virtual health coaching, have emerged as promising solutions to address these challenges. Virtual health coaching provides structured, ongoing support by using digital platforms to deliver education, reminders, and behavioral feedback. The integration of artificial intelligence (AI) into virtual coaching systems allows the intervention to be more adaptive and personalized, responding to the unique behaviors and needs of each participant. The DIACOACH application has been specifically developed to support diabetes self-management in Indonesia. It offers adaptive education modules, lifestyle modification reminders, diet and exercise monitoring, medication tracking, and a chatbot interface for personalized interaction. Early community service activities using DIACOACH have shown improvements in patient knowledge, motivation, and preliminary indicators of glycemic control such as fasting blood glucose and HbA1c levels. However, systematic research is required to evaluate its effectiveness in a controlled study, particularly in primary care contexts with limited resources.
This study is designed as a quasi-experimental trial with a non-equivalent control group design. Participants will be adults aged 30 to 56 years who have been diagnosed with T2DM for more than three months, are clinically stable, able to read, and have access to a smartphone or digital device. Individuals with type 1 diabetes, severe complications, ongoing steroid therapy, or those enrolled in other structured interventions will be excluded. Eligible participants will be recruited from primary health care centers (Puskesmas) in Jeneponto and Bantaeng, Indonesia. After baseline assessments, participants will be allocated to either the intervention group or the control group.
The intervention group will use the DIACOACH application for twelve weeks. Through this platform, participants will receive adaptive education tailored to their daily routines, reminders about diet and physical activity, and continuous encouragement to maintain self-care practices. The app integrates principles of Social Cognitive Theory and Self-Determination Theory to build self-efficacy and intrinsic motivation. The AI-based system provides feedback based on real-time data entered by participants, such as blood glucose values, diet logs, exercise activities, and medication adherence. The control group will continue with standard diabetes education typically offered at health centers, which usually consists of routine counseling sessions and printed health information.
Primary outcomes will include fasting blood glucose (FBG), HbA1c, and random blood glucose (RBG), measured at baseline and after the twelve-week intervention. Secondary outcomes will assess changes in dietary behavior, physical activity, adherence to self-care, satisfaction with the intervention, and overall quality of life. Data will be collected through laboratory tests, validated questionnaires, and digital records from the application. Quantitative data will be analyzed using appropriate statistical tests such as paired t-tests and analysis of variance to evaluate differences between groups and across time points. In addition, a qualitative component will be conducted by interviewing selected participants from the intervention group to explore their perceptions, experiences, barriers, and facilitators in using AI-based virtual coaching for diabetes self-management.
The study is expected to provide comprehensive evidence on the feasibility, acceptability, and effectiveness of AI-based virtual health coaching in primary health care. As a preliminary study, it will serve to validate the DIACOACH platform and assess its potential impact on clinical outcomes as well as patient engagement. If the intervention is found to be effective, it may offer a scalable and low-cost strategy to improve diabetes management in Indonesia, particularly in underserved and resource-constrained communities. Furthermore, this research could contribute to the integration of digital health innovations into the national primary health care system and support ongoing initiatives to reduce the burden of diabetes and its complications.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nuurhidayat Jafar, Dr
- Phone Number: +6281355576066
- Email: nuurhidayat@unhas.ac.id
Study Locations
-
-
South Sulawesi
-
Makassar, South Sulawesi, Indonesia, 90245
- Public Health Center of Bontomatene and Public Health Center of Binamu Kota
-
Contact:
- Akbar Akbar
- Phone Number: +6285299176008
- Email: akbar27021992@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Diagnosed with Type 2 Diabetes Mellitus for more than 3 months
Age between 30 and 56 years
Able to read and understand instructions
Have access to a digital device (smartphone or similar)
In stable clinical condition
Exclusion Criteria:
Diagnosed with Type 1 Diabetes Mellitus
Patients with severe complications (e.g., advanced nephropathy, retinopathy, cardiovascular disease)
Patients currently undergoing other structured interventions
Patients on long-term steroid therapy
Patients without access to a digital device
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Virtual Health Coaching (DIACOACH)
Participants in this group will receive a 12-week virtual health coaching program through the DIACOACH application.
The app provides adaptive education, reminders, self-care monitoring, and AI-based personalized feedback to support glycemic control.
|
Participants in the intervention group will receive a 12-week virtual health coaching program using the DIACOACH application.
The program includes adaptive digital education on diet, physical activity, and medication adherence, personalized reminders, daily self-monitoring, and feedback powered by artificial intelligence.
The intervention is designed to improve self-care adherence and glycemic control (FBG, HbA1c, RBG) among adults with type 2 diabetes mellitus in primary care settings.
|
|
Active Comparator: Standard Diabetes Education
Participants in this group will receive standard diabetes education provided by primary health care centers, including routine counseling sessions and printed health information.
|
Participants in the control group will receive standard diabetes education usually provided in primary health care centers.
This includes routine counseling sessions, printed educational materials, and general advice on diet, physical activity, and medication adherence, without the use of the DIACOACH application.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fasting Blood Glucose (FBG)
Time Frame: Baseline and 12 weeks after intervention
|
Change in fasting blood glucose (mg/dL) from baseline to post-intervention, measured using standardized laboratory methods
|
Baseline and 12 weeks after intervention
|
|
Glycated Hemoglobin (HbA1c)
Time Frame: Baseline and 12 weeks after intervention.
|
Change in HbA1c (%) from baseline to post-intervention, measured using standardized laboratory methods.
|
Baseline and 12 weeks after intervention.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-care Adherence
Time Frame: Baseline and 12 weeks after intervention.
|
Measured using the Summary of Diabetes Self-Care Activities (SDSCA) questionnaire.
Higher scores indicate better adherence
|
Baseline and 12 weeks after intervention.
|
|
Dietary Behavior
Time Frame: Baseline and 12 weeks after intervention.
|
Changes in dietary behavior assessed using validated dietary recall questionnaires.
|
Baseline and 12 weeks after intervention.
|
|
Physical Activity
Time Frame: Baseline and 12 weeks after intervention.
|
Measured using the International Physical Activity Questionnaire (IPAQ), reported in MET-minutes/week.
|
Baseline and 12 weeks after intervention.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UNHAS-VHC-AI-2025
- 02209/UN4.22/PT.01.03/2025 (Other Grant/Funding Number: Ministry of Education, Culture, Research, and Technology of the Republic of Indonesia)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus (T2DM)
-
Embecta Corp.Jaeb Center for Health ResearchWithdrawnType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | T2DM (Type 2 Diabetes Mellitus) | T2D | T2DM | Type 2 DM | T2DM With Inadequate Glycemic ControlUnited States
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Thymia LimitedCompletedType 2 Diabetes | Diabetes (DM) | T2DM (Type 2 Diabetes Mellitus) | T2DMUnited Kingdom
-
University of Colorado, DenverAmerican Academy of Family PhysiciansRecruitingType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | T2DM (Type 2 Diabetes Mellitus) | T2D | T2DM | Artificial Intelegence | Remote Patient MonitoringUnited States
-
Beijing HospitalRecruitingType 2 Diabetic Patients | T2DM (Type 2 Diabetes Mellitus) | T2DMChina
-
Endogenex, Inc.Enrolling by invitationDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2DiabetesAustralia, United States
-
Peking University First HospitalECHO BiotechRecruiting
-
National Taiwan University HospitalNot yet recruitingType 2 Diabetes Mellitus (T2DM)Taiwan
-
Shanghai East HospitalRecruiting
-
Carnot LaboratoriesNot yet recruitingType 2 Diabetes Mellitus (T2DM)Mexico
Clinical Trials on Virtual Health Coaching with Artificial Intelligence (DIACOACH)
-
Milton S. Hershey Medical CenterRecruitingDepression | Anxiety | Communication | Social IsolationUnited States
-
Zhongnan HospitalRecruitingLymphoma | Leukaemia | Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaChina
-
National University, SingaporeCompleted
-
Fundacao ChampalimaudEuropean Commission; Cankado GmbH; Bocconi University; INESC TEC - Institute for... and other collaboratorsActive, not recruitingBreast CancerIsrael, Italy, Germany, Poland, Portugal
-
Wake Forest University Health SciencesNot yet recruiting
-
London Metropolitan UniversityBarts & The London NHS Trust; Homerton University Hospital NHS Foundation TrustNot yet recruitingSexual Dysfunction
-
Tongren Hongxin Kangxin Traditional Chinese Medicine...CompletedAttention Deficit Hyperactivity DisorderChina
-
Spaulding Rehabilitation HospitalDeborah Munroe Noonan Memorial Research FundActive, not recruitingCerebral Palsy | Spina BifidaUnited States
-
Guy's and St Thomas' NHS Foundation TrustNot yet recruitingHeart Failure | Bradycardia | Left Bundle Branch PacingUnited Kingdom